Azenta Names Interim CEO Amid Leadership Transition

Event summary

Dr. Martin Madaus, a Carlyle Group executive and Azenta board member since 2024, appointed interim CEO following John Marotta's resignation.
Azenta reaffirms Q4 2026 revenue guidance but expects a $3M one-time consulting expense impacting adjusted EBITDA.
Board retains Heidrick & Struggles to conduct permanent CEO search.
Madaus brings 30+ years of diagnostics and life sciences leadership, including past CEO roles at Millipore and Roche Diagnostics North America.

The big picture

Azenta's leadership transition comes amid a period of strategic realignment in the life sciences tools sector, where consolidation and operational efficiency are key focus areas. Madaus' appointment reflects the board's preference for industry-specific expertise during this phase, particularly given his track record at major diagnostics firms. The move also highlights the growing influence of private equity-backed executives in shaping public life sciences companies, with Carlyle Group's $485B AUM providing additional strategic context.

What we're watching

Governance Dynamics: How the board's decision to appoint an insider as interim CEO will affect the permanent search process and strategic continuity.
Strategic Execution: Whether Madaus can leverage his industry experience to accelerate Azenta's transformation initiatives and maintain momentum from recent revenue and profitability improvements.
Financial Impact: The pace at which Azenta can absorb the $3M consulting expense and whether it signals broader operational challenges.